Baseline patient characteristics
| Characteristic . | n . | % . | Median . | Range . |
|---|---|---|---|---|
| Age, y | 61 | 28-84 | ||
| Sex | ||||
| Male | 281 | 56 | ||
| Female | 222 | 44 | ||
| Diagnosis | ||||
| MM | 454 | 90 | ||
| Nonsecretory myeloma | 38 | 8 | ||
| Extramedullary myeloma | 1 | |||
| Bence Jones proteinuria | 8 | 2 | ||
| Plasmacytoma-plus | 1 | |||
| Osteosclerotic myeloma (non-POEMS) | 1 | |||
| Treatments | ||||
| ASCT based | 290 | 58 | ||
| Non-ASCT based | ||||
| Bortezomib | 18 | 4 | ||
| Lenalidomide | 25 | 5 | ||
| Thalidomide | 2 | |||
| Carfilzomib | 2 | |||
| Pomalidomide | 3 | 1 | ||
| Bortezomib + lenalidomide | 59 | 12 | ||
| Bortezomib + thalidomide | 3 | 1 | ||
| Bortezomib + pomalidomide | 4 | 1 | ||
| Carfilzomib + lenalidomide | 6 | 1 | ||
| Carfilzomib + pomalidomide | 1 | |||
| CyBorD | 60 | 12 | ||
| VDT-PACE | 5 | 1 | ||
| Other | 25 | 5 | ||
| ISS stage | ||||
| I | 225 | 45 | ||
| II | 173 | 34 | ||
| III | 58 | 12 | ||
| Unknown | 47 | 9 | ||
| Hemoglobin, g/dL | 12.3 | 5.8-16.3 | ||
| Creatinine, mg/dL | 1 | 0.5-13.5 | ||
| β2-microglobulin, µg/mL | 2.45 | 1.2-23.3 | ||
| Calcium, mg/dL | 9.3 | 7.7-17.2 | ||
| Lactate dehydrogenase, units/L | 182 | 80-7600 | ||
| Albumin, g/dL | 3.5 | 2.1-4.5 |
| Characteristic . | n . | % . | Median . | Range . |
|---|---|---|---|---|
| Age, y | 61 | 28-84 | ||
| Sex | ||||
| Male | 281 | 56 | ||
| Female | 222 | 44 | ||
| Diagnosis | ||||
| MM | 454 | 90 | ||
| Nonsecretory myeloma | 38 | 8 | ||
| Extramedullary myeloma | 1 | |||
| Bence Jones proteinuria | 8 | 2 | ||
| Plasmacytoma-plus | 1 | |||
| Osteosclerotic myeloma (non-POEMS) | 1 | |||
| Treatments | ||||
| ASCT based | 290 | 58 | ||
| Non-ASCT based | ||||
| Bortezomib | 18 | 4 | ||
| Lenalidomide | 25 | 5 | ||
| Thalidomide | 2 | |||
| Carfilzomib | 2 | |||
| Pomalidomide | 3 | 1 | ||
| Bortezomib + lenalidomide | 59 | 12 | ||
| Bortezomib + thalidomide | 3 | 1 | ||
| Bortezomib + pomalidomide | 4 | 1 | ||
| Carfilzomib + lenalidomide | 6 | 1 | ||
| Carfilzomib + pomalidomide | 1 | |||
| CyBorD | 60 | 12 | ||
| VDT-PACE | 5 | 1 | ||
| Other | 25 | 5 | ||
| ISS stage | ||||
| I | 225 | 45 | ||
| II | 173 | 34 | ||
| III | 58 | 12 | ||
| Unknown | 47 | 9 | ||
| Hemoglobin, g/dL | 12.3 | 5.8-16.3 | ||
| Creatinine, mg/dL | 1 | 0.5-13.5 | ||
| β2-microglobulin, µg/mL | 2.45 | 1.2-23.3 | ||
| Calcium, mg/dL | 9.3 | 7.7-17.2 | ||
| Lactate dehydrogenase, units/L | 182 | 80-7600 | ||
| Albumin, g/dL | 3.5 | 2.1-4.5 |
CyBorD, cyclophosphamide, bortezomib, and dexamethasone; VDT-PACE, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide.